Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1955 1
1957 1
1959 1
1961 3
1964 3
1966 1
1967 1
1968 5
1969 3
1970 3
1971 1
1973 5
1974 1
1975 1
1976 1
1977 2
1978 3
1979 1
1980 1
1981 1
1984 1
1985 2
1990 1
1991 3
1992 2
1994 2
1995 1
1997 3
2000 3
2003 4
2006 3
2007 3
2008 3
2009 5
2010 7
2011 21
2012 27
2013 23
2014 24
2015 32
2016 31
2017 30
2018 30
2019 42
2020 49
2021 58
2022 49
2023 36
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

481 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenesis of rheumatoid arthritis: one year in review 2022.
Petrelli F, Mariani FM, Alunno A, Puxeddu I. Petrelli F, et al. Clin Exp Rheumatol. 2022 Mar;40(3):475-482. doi: 10.55563/clinexprheumatol/l9lyen. Epub 2022 Mar 10. Clin Exp Rheumatol. 2022. PMID: 35333708 Free article. Review.
One year in review 2020: pathogenesis of rheumatoid arthritis.
Giannini D, Antonucci M, Petrelli F, Bilia S, Alunno A, Puxeddu I. Giannini D, et al. Among authors: petrelli f. Clin Exp Rheumatol. 2020 May-Jun;38(3):387-397. doi: 10.55563/clinexprheumatol/3uj1ng. Epub 2020 Apr 23. Clin Exp Rheumatol. 2020. PMID: 32324123 Free article. Review.
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J, Ma X, Ooft SN, van der Helm PW, Hoes LR, Mainardi S, Pinato DJ, Sun K, Salvatore L, Tortora G, Zurlo IV, Leo S, Giampieri R, Berardi R, Gelsomino F, Merz V, Mazzuca F, Antonuzzo L, Rosati G, Stavraka C, Ross P, Rodriquenz MG, Pavarana M, Messina C, Iveson T, Zoratto F, Thomas A, Fenocchio E, Ratti M, Depetris I, Cergnul M, Morelli C, Libertini M, Parisi A, De Tursi M, Zanaletti N, Garrone O, Graham J, Longarini R, Gobba SM, Petrillo A, Tamburini E, La Verde N, Petrelli F, Ricci V, Wessels LFA, Ghidini M, Cortellini A, Voest EE, Valeri N. van de Haar J, et al. Among authors: petrelli f. Nat Med. 2023 Mar;29(3):605-614. doi: 10.1038/s41591-023-02240-8. Epub 2023 Mar 2. Nat Med. 2023. PMID: 36864254 Free PMC article. Clinical Trial.
Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Amoroso V, et al. Among authors: petrelli f. ESMO Open. 2023 Apr;8(2):100787. doi: 10.1016/j.esmoop.2023.100787. Epub 2023 Feb 24. ESMO Open. 2023. PMID: 36842300 Free PMC article. Review.
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M, Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, Zamagni C, Chini C, Ruepp B, Loi S, Colleoni M; International Breast Cancer Study Group (IBCSG). Munzone E, et al. Among authors: petrelli f. JAMA Oncol. 2023 Sep 1;9(9):1267-1272. doi: 10.1001/jamaoncol.2023.2150. JAMA Oncol. 2023. PMID: 37440239 Clinical Trial.
481 results